Testosterone and Aging
The Normal Trajectory vs. Disease, Distinguishing Age-Related Decline from Hypogonadism
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Age-related decline is not an FDA-approved TRT indication
Reference only. Not medical advice.
What can go wrong
Treating normal aging as disease exposes men to TRT's documented risks (fertility suppression, polycythemia, dependence on lifelong therapy) for limited proven benefit. Diagnosis requires repeated morning total testosterone plus consistent symptoms per Endocrine Society guidance.
This is something to take to a clinician. The Atlas can tell you what is known about testosterone and aging in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Testosterone declines gradually with age in most men, roughly 1-2% per year after about age 30-40, but this normal trajectory is distinct from pathological hypogonadism, which requires both consistently low morning testosterone and consistent symptoms. The FDA explicitly warns that testosterone is approved for classical (organic) hypogonadism, not for the natural decline of aging. Much of age-related testosterone decline is mediated by accumulating comorbidities (obesity, diabetes, poor sleep) rather than aging per se, which is why the European Male Ageing Study found 'late-onset hypogonadism' is uncommon when defined rigorously.
Getting older is not a disease, but the line between normal and pathological is genuinely blurry.
How it is supposed to work
Aging reduces both Leydig cell testosterone production and the pulsatility of pituitary LH signaling, while sex-hormone-binding globulin (SHBG) tends to rise, lowering free testosterone disproportionately. Comorbid obesity increases aromatization of testosterone to estradiol and suppresses the HPG axis, compounding the age effect.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Repeat morning total testosterone before any diagnosis
- Hematocrit
- PSA where treatment considered
- Evaluation of comorbidities (BMI, sleep apnea, diabetes)
What people get wrong
Often saidFalling testosterone with age is a disease that should be corrected
ActuallyAge-related decline alone is not an FDA-approved indication for TRT. Treatment is warranted for diagnosed hypogonadism with symptoms and confirmed low levels, not simply for being older.
Often saidEvery tired older man has 'low T'
ActuallyFatigue is nonspecific. Much age-related decline is driven by treatable comorbidities; addressing obesity, sleep apnea, and inactivity often matters more than the number on a lab report.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
The marketing concept of 'andropause' or 'male menopause' implied a discrete, treatable life stage analogous to female menopause. Endocrinologists largely reject that framing: male decline is gradual and variable, not a universal abrupt transition, and most aging men retain testosterone in the normal range.
The people taking it
Concerns concentrate in men over 40; the most rigorous prevalence data (EMAS) show true late-onset hypogonadism is far less common than questionnaire-based marketing suggests.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Testosterone and Aging. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Wu et al., NEJM, European Male Ageing Study (EMAS)2010
Defined late-onset hypogonadism by 3 sexual symptoms plus low T; by that rigorous standard prevalence was only ~2%, far below symptom-questionnaire estimates
Harman et al., Baltimore Longitudinal Study of Aging2001
Longitudinal data showed an average decline of ~1-2%/year in total testosterone with age, with free T falling faster due to rising SHBG
Snyder et al., NEJM, Testosterone Trials (T-Trials)2016
In men 65+ with unequivocally low T, testosterone modestly improved sexual function and mood but had mixed or null effects on vitality, cognition, and physical function
Travison et al.2007
Showed the age-related decline coexists with a separate cohort (secular) decline